3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

EFFECT - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

F-1 - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

20-F - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that shareholders have approved all five resolutions at the company's 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high‑vote Class B shares, a targeted share exchange with a major shareholder, and a large‑scale share consolidation. Authorised Share Capital Changes Shareholders resolved by an ordinary resolution that, the Company authorised share capital of the Company be amended in the manner and sequence set out below with immediate effect (collectively, the Authorise

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that it has entered into a non-binding memorandum (the "Investment Memorandum") with Future Biotechnology Group Co., Ltd (hereinafter referred to as "Future Biotechnology Group"). The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the "Consideration Shares"). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation perio

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") today announced that it has entered into a series of share purchase agreements with several investors. Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. This round of investment further strengthens the company's long-term development in biopharmaceutical R

Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (the "Company") today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter. On November 24, 2025, Ping An Biomedical Co., Ltd. (the "Company") received a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Nasdaq has provided the Company with an 180 calendar days complianc